Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

77 comunicati stampa

Guarda tutti i comunicati
12/12/2025
Farmaceutica
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
12/12/2025
Farmaceutica
Medicina Salute Benessere
Teva Releases Q4 2025 Aide Memoire
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmaceutica
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/11/2025
Farmaceutica
Annunci Economici
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/11/2025
Farmaceutica
Annunci Economici
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/11/2025
Farmaceutica
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmaceutica
Annunci Economici
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
07/11/2025
Farmaceutica
Medicina Salute Benessere
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/11/2025
Farmaceutica
Management/Organizzazione Aziendale
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
03/11/2025
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0